Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Exp Rheumatol ; 40(9): 1718-1725, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-34936549

RESUMO

OBJECTIVES: Dysregulation of IL-12 and IL-23 is related to many autoimmune diseases including arthritis. The production of IL-12 and IL-23 were reported to be under the control of JMJD2D, whose activity and stability were promoted by the TRAF-binding domain (TRABID), a deubiquitinating enzyme that epigenetically modulated inflammatory gene expression. NSC1122002 is a novel inhibitor of TRABID, and this study aimed to examine the effects of NSC1122002 on the expression of IL-12 and IL-23 both in vitro and in vivo in the context of collagen-induced arthritis, consequently to evaluate its potential as a drug candidate for treating inflammatory disease. METHODS: Bone marrow cells were isolated to detect the effect of NSC1122002 on the development of innate immune cells and other precursor cells. Primary macrophages and osteoclasts were used to examine the impact of NSC1122002 on cytokine expression. Collagen-induced arthritis was established to determine the function of NSC1122002 in vivo. RESULTS: NSC112200 did not affect the development of innate immune cells, primary osteoclast, and haematopoietic stem cells. NSC112200 specifically downregulated the expression of IL-12 and IL-23 through promoting degradation of JMJD2D by directly inhibited the deubiquitinating activity of TRABID. Besides, NSC112200 significantly suppressed the induction of CIA in mice. CONCLUSIOINS: Our findings provided new insight into the pathological mechanism and intervention method for arthritis therapy and identified that NSC112200 could be a potential drug for treating autoimmune diseases.


Assuntos
Artrite Experimental , Doenças Autoimunes , Animais , Artrite Experimental/induzido quimicamente , Artrite Experimental/tratamento farmacológico , Citocinas/metabolismo , Enzimas Desubiquitinantes/uso terapêutico , Modelos Animais de Doenças , Interleucina-12 , Interleucina-23 , Camundongos , Camundongos Endogâmicos DBA , Osteoclastos/metabolismo
2.
J Mol Neurosci ; 64(2): 321-330, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29352446

RESUMO

Mycobacterium tuberculosis (M. tuberculosis) invading and activating microglia causes the most serious subtypes of tuberculosis called tubercular meningitis. However, the developmental process of tubercular meningitis, especially the early phase, is poorly understood due to lacking well-established and well-accepted visible models in vitro and in vivo. Here, consistent with one recent report, we found Mycobacterium marinum (M. marinum) invade the zebrafish brain and subsequently cause granuloma-like structures. We further showed that M. marinum, which shares similar characteristics with M. tuberculosis, can invade microglia and replicate in microglia, which subsequently promote the secretion of pro-inflammatory cytokines such as IL-1ß, IL-6, and TNF-α. M. marinum infection in microglia can also promote autophagy, which conversely limits the replication of M. marinum. Thus, pharmacological activation of autophagy by rapamycin could prevent M. marinum replication. Our study provides in vivo and in vitro models to study underlying pathogenic mechanisms of tubercular meningitis by using M. marinum. Our results also showed that activation of autophagy could be a meaningful way to prevent tubercular meningitis.


Assuntos
Encéfalo/microbiologia , Microglia/metabolismo , Infecções por Mycobacterium/patologia , Mycobacterium marinum/patogenicidade , Animais , Autofagia , Encéfalo/metabolismo , Encéfalo/patologia , Linhagem Celular , Células Cultivadas , Citocinas/genética , Citocinas/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Microglia/microbiologia , Microglia/patologia , Infecções por Mycobacterium/metabolismo , Infecções por Mycobacterium/microbiologia , Peixe-Zebra
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA